Trends of measles in Tanzania: a five-year review of case-based surveillance data, 2018-2022
Vaccines provide a safe and cost-effective solution to vaccine-preventable infectious diseases. However, vaccine-preventable infectious diseases still pose a serious public health threat especially in the world's poor regions[1]. In sub-Saharan Africa, this burden is further aggravated by the occurrence of concurrent epidemics such as Coronavirus Disease 2019 (COVID-19), Ebola virus disease, monkeypox, and measles overstretching the already weak public health system[2]. In addition to human conflicts, natural disasters, vaccine hesitancy, and the COVID-19 pandemic has disrupted routine immunisation services leaving million...
Source: International Journal of Infectious Diseases - December 17, 2023 Category: Infectious Diseases Authors: Fausta Michael, Mariam M. Mirambo, Gerald Misinzo, Omary Minzi, Medard Beyanga, Delphinus Mujuni, Florence S Kalabamu, Elias N Nyanda, Mary Mwanyika-Sando, Daniel Ndiyo, Richard Kasonogo, Abbas Ismail, Andrew Bahati, Farida Hassan, Elangiringa Kaale, John Source Type: research
Trends of measles in Tanzania: A 5-year review of case-based surveillance data, 2018-2022
Vaccines provide a safe and cost-effective solution to vaccine-preventable infectious diseases. However, vaccine-preventable infectious diseases still pose a serious public health threat, especially in the world's poor regions [1]. In sub-Saharan Africa, this burden is further aggravated by the occurrence of concurrent epidemics such as COVID-19, Ebola virus disease, monkeypox, and measles overstretching the already weak public health system [2]. In addition to human conflicts, natural disasters, and vaccine hesitancy, the COVID-19 pandemic has disrupted routine immunization services leaving millions of children under-vacc...
Source: International Journal of Infectious Diseases - December 17, 2023 Category: Infectious Diseases Authors: Fausta Michael, Mariam M. Mirambo, Gerald Misinzo, Omary Minzi, Medard Beyanga, Delphinus Mujuni, Florence S. Kalabamu, Elias N. Nyanda, Mary Mwanyika-Sando, Daniel Ndiyo, Richard Kasonogo, Abbas Ismail, Andrew Bahati, Farida Hassan, Eliangiringa Kaale, J Source Type: research
Policy responses to the COVID-19 pandemic in West Africa: a scoping review protocol
The objective of this scoping review is to understand the extent and type of evidence in relation to the policy formulation, decision-making and implementation stages of NPIs in West Africa.
Methods and analysis
A scoping review will be undertaken following the guidance developed by Arskey and O’Malley, the Joanna Briggs Institute (JBI) methodology for scoping reviews and the PRISMA guidelines for Scoping Reviews. Both peer-reviewed and grey literature will be searched using Web of Science, Embase, Scopus, APA PsycInfo, WHO Institutional Repository for Information Sharing, JSTOR and Google Advanced Search, and by se...
Source: BMJ Open - December 10, 2023 Category: General Medicine Authors: Fischer, H.-T., Müller, K., Wenham, C., Hanefeld, J. Tags: Open access, Global health, COVID-19 Source Type: research
Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice
In this study, we demonstrated the antiviral effects of PIKfyve inhibitors on influenza virus and respiratory syncytial virus in vitro and in vivo. PIKfyve inhibitors Apilimod mesylate (AM) and YM201636 concentration-dependently inhibited several influenza strains in an MDCK cell-cytopathic assay. AM also reduced the viral load and cytokine release, while improving the cell integrity of human nasal air-liquid interface cultured epithelium infected with influenza PR8. In PR8-infected mice, AM (2 mg/mL), when intranasally treated, exhibited a significant reduction of viral load and inflammation and inhibited weight loss caus...
Source: Antimicrobial Agents and Chemotherapy - December 8, 2023 Category: Microbiology Authors: Jonathan Baker Hugo Ombredane Leah Daly Ian Knowles Garth Rapeport Kazuhiro Ito Source Type: research
Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice
In this study, we demonstrated the antiviral effects of PIKfyve inhibitors on influenza virus and respiratory syncytial virus in vitro and in vivo. PIKfyve inhibitors Apilimod mesylate (AM) and YM201636 concentration-dependently inhibited several influenza strains in an MDCK cell-cytopathic assay. AM also reduced the viral load and cytokine release, while improving the cell integrity of human nasal air-liquid interface cultured epithelium infected with influenza PR8. In PR8-infected mice, AM (2 mg/mL), when intranasally treated, exhibited a significant reduction of viral load and inflammation and inhibited weight loss caus...
Source: Antimicrobial Agents and Chemotherapy - December 8, 2023 Category: Microbiology Authors: Jonathan Baker Hugo Ombredane Leah Daly Ian Knowles Garth Rapeport Kazuhiro Ito Source Type: research
Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice
In this study, we demonstrated the antiviral effects of PIKfyve inhibitors on influenza virus and respiratory syncytial virus in vitro and in vivo. PIKfyve inhibitors Apilimod mesylate (AM) and YM201636 concentration-dependently inhibited several influenza strains in an MDCK cell-cytopathic assay. AM also reduced the viral load and cytokine release, while improving the cell integrity of human nasal air-liquid interface cultured epithelium infected with influenza PR8. In PR8-infected mice, AM (2 mg/mL), when intranasally treated, exhibited a significant reduction of viral load and inflammation and inhibited weight loss caus...
Source: Antimicrobial Agents and Chemotherapy - December 8, 2023 Category: Microbiology Authors: Jonathan Baker Hugo Ombredane Leah Daly Ian Knowles Garth Rapeport Kazuhiro Ito Source Type: research
Understanding knowledge, attitudes and practices on Ebola Virus Disease: a multi-site mixed methods survey on preparedness in Rwanda
The overall goal of this survey was to understand the knowledge, attitudes, and practices related to the Ebola Virus Disease (EVD) in Rwanda. (Source: BMC Public Health)
Source: BMC Public Health - December 5, 2023 Category: Consumer Health News Authors: Janvier Karuhije, Menelas Nkeshimana, Fathiah Zakham, Benjamin Hewins, Justin Rutayisire, Gustavo Sganzerla Martinez, David Kelvin and Pacifique Ndishimye Tags: Research article Source Type: research
Systems analysis of the effects of the 2014-16 Ebola crisis on WHO-reporting nations ’ policy adaptations and 2020-21 COVID-19 response: a systematized review
Recent case studies indicate that the 2014-2016 Ebola outbreak, one of the worst pre-2020 global biological catastrophes in modern history, helped some nations to better prepared their responses for the COVID-... (Source: Globalization and Health)
Source: Globalization and Health - December 5, 2023 Category: International Medicine & Public Health Authors: Jessi Hanson-DeFusco, Min Shi, Zoe Du, Ornheilia Zounon, Fid èle Marc Hounnouvi and Albert DeFusco Tags: Research Source Type: research
Performance of a safe and dignified burial intervention during an Ebola epidemic in the eastern Democratic Republic of the Congo, 2018 –2019
A protracted Ebola Virus Disease (EVD) epidemic in the eastern Ituri, North and South Kivu provinces of the Democratic Republic of Congo (DRC) caused 3470 confirmed and probable cases between July 2018 and Apr... (Source: BMC Medicine)
Source: BMC Medicine - December 5, 2023 Category: Internal Medicine Authors: Abdihamid Warsame, Gwendolen Eamer, Alaria Kai, Lucia Robles Dios, Hana Rohan, Patrick Keating, Jacques Katshishi and Francesco Checchi Tags: Research article Source Type: research
Quality of life and factors associated among caregivers of adolescent and young adult Ebola survivors in Democratic Republic of the Congo, a cross-sectional study
Ebola virus disease is a medical condition whose consequent effects on quality of life of patients. In the history of infectious diseases, there have been pathologies that have had significant repercussions fo... (Source: BMC Public Health)
Source: BMC Public Health - November 29, 2023 Category: Consumer Health News Authors: Kisughu Munyumu, Charles Wafula, Vincent Were, Fran çoise Katungu, Ndemo Mbasa and Margaret Kaseje Tags: Research Source Type: research
Viruses, Vol. 15, Pages 2329: Discovery and Characterization of IFITM S-Palmitoylation
ang
Interferon-induced transmembrane proteins (IFITM1, 2 and 3) are important host antiviral defense factors. They are active against viruses like the influenza A virus (IAV), dengue virus (DENV), Ebola virus (EBOV), Zika virus (ZIKV) and severe acute respiratory syndrome coronavirus (SARS-CoV). In this review, we focus on IFITM3 S-palmitoylation, a reversible lipid modification, and describe its role in modulating IFITM3 antiviral activity. Our laboratory discovered S-palmitoylation of IFITMs using chemical proteomics and demonstrated the importance of highly conserved fatty acid-modified Cys residues in IFITM3 antivi...
Source: Viruses - November 28, 2023 Category: Virology Authors: Tandrila Das Howard C. Hang Tags: Review Source Type: research
Viruses, Vol. 15, Pages 2322: New Insights into the Applications of Viruses to Biotechnology
nda
Viruses are responsible for many devastating human and animal diseases, such as Ebola, rabies, HIV, smallpox, influenza, dengue, and SARS-CoV-2 [...] (Source: Viruses)
Source: Viruses - November 26, 2023 Category: Virology Authors: Patrick Materatski Carla Varanda Tags: Editorial Source Type: research
Lactic acid bacterial surface display of scytovirin inhibitors for anti-ebolavirus infection
Scytovirin (SVN) is a lectin from cyanobacteria which has a strong inhibitory activity against Ebola virus infection. We engineered scytovirin as the inhibitor for surface display of lactic acid bacteria to block Ebola virus infection. Two different bacterial strains (Lactobacillus casei and Lactococcus lactis) were successfully engineered for scytovirin expression on the bacterial surface. These bacteria were found to be effective at neutralizing pseudotyped Ebolavirus in a cell-based assay. This approach can be utilized for prophylactic prevention, as well as for treatment. Since lactic acid bacteria can colonize the hum...
Source: Frontiers in Microbiology - November 23, 2023 Category: Microbiology Source Type: research
Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned
Vaccine. 2023 Nov 21:S0264-410X(23)01363-4. doi: 10.1016/j.vaccine.2023.11.030. Online ahead of print.ABSTRACTConducting a vaccine trial in a low- and middle-income country (LMIC) can present unique challenges and lessons learned. This Ebola vaccine trial, enrolling 699 healthcare providers and frontliners and jointly set up by the University of Antwerp (Sponsor) and the University of Kinshasa (Principal Investigator (PI)), was conducted in Boende, a remote city in the Democratic Republic of the Congo (DRC), between December 2019 and October 2022 (ClinicalTrials.gov: NCT04186000). While being bound by strict ICH-GCP and in...
Source: Vaccine - November 22, 2023 Category: Allergy & Immunology Authors: Ynke Larivi ère Tr ésor Zola Matuvanga Gwen Lemey Bernard Isekah Osang'ir Paul Peter Vermeiren Solange Milolo Rachel Meta Primo Kimbulu Emmanuel Esanga Junior Matangila Jean-Pierre Van Geertruyden Pierre Van Damme Vivi Maketa Hypolite Muhindo-Mavoko Pat Source Type: research
Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned
Vaccine. 2023 Nov 21:S0264-410X(23)01363-4. doi: 10.1016/j.vaccine.2023.11.030. Online ahead of print.ABSTRACTConducting a vaccine trial in a low- and middle-income country (LMIC) can present unique challenges and lessons learned. This Ebola vaccine trial, enrolling 699 healthcare providers and frontliners and jointly set up by the University of Antwerp (Sponsor) and the University of Kinshasa (Principal Investigator (PI)), was conducted in Boende, a remote city in the Democratic Republic of the Congo (DRC), between December 2019 and October 2022 (ClinicalTrials.gov: NCT04186000). While being bound by strict ICH-GCP and in...
Source: Vaccine - November 22, 2023 Category: Allergy & Immunology Authors: Ynke Larivi ère Tr ésor Zola Matuvanga Gwen Lemey Bernard Isekah Osang'ir Paul Peter Vermeiren Solange Milolo Rachel Meta Primo Kimbulu Emmanuel Esanga Junior Matangila Jean-Pierre Van Geertruyden Pierre Van Damme Vivi Maketa Hypolite Muhindo-Mavoko Pat Source Type: research
